Daewoong Pharmaceutical, Institutional Investors Net Buy 50,043 Shares in Last 5 Days... Stock Price 144,500 KRW (-7.07%)

Daewoong Pharmaceutical is trading at 144,500 KRW as of 11:31 AM on the 23rd, down 7.07% from the previous day. The trading volume is 144,752 shares, which is 12.66% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On February 22, researcher Lee Hyerin of KTB Investment & Securities stated, "Evolus Abbvie (Allergan)/Medytox successfully reached a final agreement to end intellectual property litigation in the United States, judged to be the best outcome where all three parties in the detailed agreement are win-win. Regardless of the 21-month import ban period, Nabota sales in the U.S. are expected to resume soon, which is a positive issue for the company’s stock excluded from the agreement process. The target price was significantly raised by restoring the export business value of Nabota, which had been zeroed out." She announced Daewoong Pharmaceutical’s target price at 210,000 KRW.

Over the past five days, individual investors have net sold 9,960 shares of Daewoong Pharmaceutical, while foreigners and institutions have net sold 40,258 shares and net bought 50,043 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.